Eterna Therapeutics develops off-the-shelf cellular therapies using induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) that express pro-inflammatory cytokines IL-7 and IL-15 to target solid tumors. This approach addresses the limitations of traditional MSC therapies by providing a consistent and scalable source of cells that enhance T-cell anti-tumor activity while minimizing systemic exposure and toxicity.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional mesenchymal stem cell (MSC) therapies for solid tumors suffer from inconsistent therapeutic outcomes due to MSC heterogeneity, batch-to-batch variability, limited proliferative capacity, and early senescence. These limitations hinder the development of scalable and reliable off-the-shelf cell therapies.
Solution
Eterna Therapeutics is developing off-the-shelf cellular therapies using induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) to address the limitations of traditional MSC therapies. Their proprietary mRNA-based platform enhances iPSC generation, enabling a scalable iMSC product that delivers pro-inflammatory cytokines (e.g., IL-7 and IL-15) selectively to tumors. This targeted approach limits systemic exposure and potential toxicity while enhancing T-cell anti-tumor activity. By using iMSCs, Eterna aims to provide a consistent and rejuvenated source for allogeneic therapies.
Target Audience
The primary target audience includes patients with advanced solid tumors and the clinicians treating them.
Features
- iMSCs derived from homogeneous, well-characterized cell lines under controlled conditions
- Proprietary mRNA-based platform enhances iPSC generation
- Designed to deliver IL-7/IL-15 selectively to tumors
- Enhanced T-cell anti-tumor activity
- Scalable, off-the-shelf iMSC product